


We claim:


1. A composition having the formula:

5



wherein:

$X^1$  is selected from:



10

$X^2$  is selected from O, NR and S;


$Y^1$  is independently O, S, NR,  $^+N(O)(R)$ ,  $^+N(OR)$ ,  $^+N(O)(OR)$ , or  $N-NR_2$ ;

$Y^2$  is independently a bond, O, NR,  $^+N(O)(R)$ ,  $^+N(OR)$ ,  $^+N(O)(OR)$ ,  $N-NR_2$ ,  $-S(O)_{M2}-$ , or  $-S(O)_{M2}-S(O)_{M2}-$ ;

$Y^3$  and Z are independently selected from H, OH, OR,  $NR_2$ , CN,  $NO_2$ , F, Cl, Br, and

15 I;

$R^x$  is independently H,  $W^3$ , a protecting group, or the formula:



wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and

5  $R^y$  is independently H,  $W^3$ , or a protecting group;

M2 is 0, 1 or 2;

$R^1, R^2, R^3, R^4, R^5, R^6, R^7$ , and  $R^8$  are independently selected from H, F, Cl, Br, I, OH,  $-C(=Y^1)R$ ,  $-C(=Y^1)OR$  or  $-C(=Y^1)N(R)_2$ ,  $-N(R)_2$ ,  $-N(R)_3$ ,  $-SR$ ,  $-S(O)R$ ,  $-S(O)_2R$ ,  $-S(O)(OR^x)$ ,  $-S(O)_2(OR^x)$ ,  $-OC(=Y^1)R^x$ ,  $-OC(=Y^1)OR^x$ ,  $-OC(=Y^1)(N(R^x)_2)$ ,  $-SC(=Y^1)R^x$ ,  $-SC(=Y^1)OR^x$ ,  $-SC(=Y^1)(N(R^x)_2)$ ,  $-N(R^x)C(=Y^1)R^x$ ,  $-N(R^x)C(=Y^1)OR^x$ , or  $-N(R^x)C(=Y^1)N(R^x)_2$ , amino ( $-NH_2$ ), ammonium ( $-NH_3^+$ ), alkylamino, dialkylamino, trialkylammonium,  $C_1-C_8$  alkyl,  $C_1-C_8$  alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam,  $C_1-C_8$  alkylsulfonate,  $C_1-C_8$  alkylamino, 4-dialkylaminopyridinium,  $C_1-C_8$  alkylhydroxyl,  $C_1-C_8$  alkylthiol, alkylsulfone ( $-SO_2R$ ), arylsulfone ( $-SO_2Ar$ ), arylsulfoxide ( $-SOAr$ ), arylthio ( $-SAr$ ), sulfonamide ( $-SO_2NR_2$ ), alkylsulfoxide ( $-SOR$ ), ester ( $-C(=O)OR$ ), amido ( $-C(=O)NR_2$ ), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile ( $-CN$ ), azido ( $-N_3$ ), nitro ( $-NO_2$ ),  $C_1-C_8$  alkoxy ( $-OR$ ),  $C_1-C_8$  alkyl,  $C_1-C_8$  substituted alkyl,  $C_1-C_8$  alkenyl,  $C_1-C_8$  substituted alkenyl,  $C_1-C_8$  alkynyl,  $C_1-C_8$  substituted alkynyl,  $C_6-C_{20}$  aryl,  $C_6-C_{20}$  substituted aryl,  $C_2-C_{20}$  heteroaryl,  $C_2-C_{20}$  substituted heteroaryl, polyethyleneoxy, and  $W^3$ ; or

when taken together, two of  $R^1, R^2, R^3, R^4, R^5, R^6, R^7$ , and  $R^8$  form a carbocyclic ring of 3 to 7 carbon atoms;

R is  $C_1-C_8$  alkyl,  $C_1-C_8$  substituted alkyl,  $C_1-C_8$  alkenyl,  $C_1-C_8$  substituted alkenyl,  $C_1-C_8$  alkynyl,  $C_1-C_8$  substituted alkynyl,  $C_6-C_{20}$  aryl,  $C_6-C_{20}$  substituted aryl,  $C_2-C_{20}$  heteroaryl,  $C_2-C_{20}$  substituted heteroaryl;


$W^3$  is  $W^4$  or  $W^5$ ;

$W^4$  is R,  $-C(Y^1)R$ ,  $-C(Y^1)W^5$ ,  $-SO_2R$ , or  $-SO_2W^5$ ;


$W^5$  is carbocycle or heterocycle wherein  $W^5$  is independently substituted with 0 to 3 R groups;

with the proviso that when  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are each H,  $Y^1$  and  $Y^2$  are O and M2 is 0, then  $R^x$  is not H.

- 5            2.        The composition of claim 1 wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are H.
3.        The composition of claim 1 wherein  $R^3$  is C<sub>1-8</sub> alkyl.
4.        The composition of claim 1 wherein  $R^3$  is C<sub>1-8</sub> substituted alkyl.
5.        The composition of claim 4 wherein  $R^3$  is 1-hydroxyethyl.
6.        The composition of claim 1 wherein  $R^5$  is C<sub>1-8</sub> alkyl.
- 10           7.        The composition of claim 1 wherein  $R^5$  is C<sub>1-8</sub> substituted alkyl.
8.        The composition of claim 7 wherein  $R^5$  is 1-hydroxyethyl.
9.        The composition of claim 1 having the formula:




- 10           10.       The composition of claim 3 wherein  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are H.
- 15           11.       A composition having the formula:



wherein:

$X^1$  is selected from:




$X^2$  is selected from O, NR and S;

$Y^1$  is independently O, S, NR,  $^+N(O)(R)$ ,  $^+N(OR)$ ,  $^+N(O)(OR)$ , or  $N-NR_2$ ;

5  $Y^2$  is independently a bond, O, NR,  $^+N(O)(R)$ ,  $^+N(OR)$ ,  $^+N(O)(OR)$ ,  $N-NR_2$ ,  $-S(O)_{M2}$ , or  $-S(O)_{M2}-S(O)_{M2}$ ;

$Y^3$  and Z are independently selected from H, OH, OR,  $NR_2$ , CN,  $NO_2$ , F, Cl, Br, and I;

$R^x$  is independently H,  $W^3$ , a protecting group, or the formula:



wherein:

M1a, M1c, and M1d are independently 0 or 1;

M12c is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12; and

$R^y$  is independently H,  $W^3$ , or a protecting group;

15 M2 is 0, 1 or 2;

$R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$ ,  $R^5$ ,  $R^6$ ,  $R^7$ , and  $R^8$  are independently selected from H, F, Cl, Br, I, OH,  $-C(=Y^1)R$ ,  $-C(=Y^1)OR$  or  $-C(=Y^1)N(R)_2$ ,  $-N(R)_2$ ,  $^+N(R)_3$ ,  $-SR$ ,  $-S(O)R$ ,  $-S(O)_2R$ ,  $-S(O)(OR^x)$ ,  $-S(O)_2(OR^x)$ ,  $-OC(=Y^1)R^x$ ,  $-OC(=Y^1)OR^x$ ,  $-OC(=Y^1)(N(R^x)_2)$ ,  $-SC(=Y^1)R^x$ ,  $-SC(=Y^1)OR^x$ ,  $-SC(=Y^1)(N(R^x)_2)$ ,  $-N(R^x)C(=Y^1)R^x$ ,  $-N(R^x)C(=Y^1)OR^x$ , or -

20  $N(R^x)C(=Y^1)N(R^x)_2$ , amino ( $-NH_2$ ), ammonium ( $-NH_3^+$ ), alkylamino, dialkylamino,

trialkylammonium, C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> alkylhalide, carboxylate, sulfate, sulfamate, sulfonate, 5-7 membered ring sultam, C<sub>1</sub>–C<sub>8</sub> alkylsulfonate, C<sub>1</sub>–C<sub>8</sub> alkylamino, 4-dialkylaminopyridinium, C<sub>1</sub>–C<sub>8</sub> alkylhydroxyl, C<sub>1</sub>–C<sub>8</sub> alkylthiol, alkylsulfone (–SO<sub>2</sub>R), arylsulfone (–SO<sub>2</sub>Ar), arylsulfoxide (–SOAr), arylthio (–SAr), sulfonamide (–SO<sub>2</sub>NR<sub>2</sub>),

5 alkylsulfoxide (–SOR), ester (–C(=O)OR), amido (–C(=O)NR<sub>2</sub>), 5-7 membered ring lactam, 5-7 membered ring lactone, nitrile (–CN), azido (–N<sub>3</sub>), nitro (–NO<sub>2</sub>), C<sub>1</sub>–C<sub>8</sub> alkoxy (–OR), C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> substituted alkyl, C<sub>1</sub>–C<sub>8</sub> alkenyl, C<sub>1</sub>–C<sub>8</sub> substituted alkenyl, C<sub>1</sub>–C<sub>8</sub> alkynyl, C<sub>1</sub>–C<sub>8</sub> substituted alkynyl, C<sub>6</sub>–C<sub>20</sub> aryl, C<sub>6</sub>–C<sub>20</sub> substituted aryl, C<sub>2</sub>–C<sub>20</sub> heteroaryl, C<sub>2</sub>–C<sub>20</sub> substituted heteroaryl, polyethyleneoxy, and W<sup>3</sup>; or

10 when taken together, two of R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> form a carbocyclic ring of 3 to 7 carbon atoms;

R is C<sub>1</sub>–C<sub>8</sub> alkyl, C<sub>1</sub>–C<sub>8</sub> substituted alkyl, C<sub>1</sub>–C<sub>8</sub> alkenyl, C<sub>1</sub>–C<sub>8</sub> substituted alkenyl, C<sub>1</sub>–C<sub>8</sub> alkynyl, C<sub>1</sub>–C<sub>8</sub> substituted alkynyl, C<sub>6</sub>–C<sub>20</sub> aryl, C<sub>6</sub>–C<sub>20</sub> substituted aryl, C<sub>2</sub>–C<sub>20</sub> heteroaryl, C<sub>2</sub>–C<sub>20</sub> substituted heteroaryl;

15 W<sup>3</sup> is W<sup>4</sup> or W<sup>5</sup>;

W<sup>4</sup> is R, –C(Y<sup>1</sup>)R, –C(Y<sup>1</sup>)W<sup>5</sup>, –SO<sub>2</sub>R, or –SO<sub>2</sub>W<sup>5</sup>;

W<sup>5</sup> is carbocycle or heterocycle wherein W<sup>5</sup> is independently substituted with 0 to 3 R groups;

20 with the proviso that when R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, and R<sup>8</sup> are each H, Y<sup>1</sup> and Y<sup>2</sup> are O and M<sub>2</sub> is 0, then R<sup>x</sup> is not H.

12. The composition of claim 5 wherein NUCLEOBASE is selected from adenine, guanine, cytosine, uracil, thymine, 7-deazaadenine, 7-deazaguanine, 7-deaza-8-azaguanine, 7-deaza-8-azaadenine, inosine, nebularine, nitropyrrole, nitroindole, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, pseudouridine, 25 pseudocytosine, pseudoisocytosine, 5-propynylcytosine, isocytosine, isoguanine, 7-deazaguanine, 2-thiopyrimidine, 6-thioguanine, 4-thiiothymine, 4-thiouracil, O<sup>6</sup>-methylguanine, N<sup>6</sup>-methyladenine, O<sup>4</sup>-methylthymine, 5,6-dihydrothymine, 5,6-dihydrouracil, 4-methylindole, and a pyrazolo[3,4-D]pyrimidine.

13. The composition of claim 11 wherein R<sub>3</sub> is C<sub>1-8</sub> alkyl.

30 14. The composition of claim 11 wherein R<sub>3</sub> is C<sub>1-8</sub> substituted alkyl.

15. The composition of claim 14 wherein R<sub>3</sub> is 1-hydroxyethyl.
16. The composition of claim 11 wherein R<sub>5</sub> is C<sub>1-8</sub> alkyl.
17. The composition of claim 11 wherein R<sub>5</sub> is C<sub>1-8</sub> substituted alkyl.
18. The composition of claim 17 wherein R<sub>5</sub> is 1-hydroxyethyl.

5           19. A method for the treatment or prevention of the symptoms or effects of HIV infection in an infected animal comprising administering said animal with a pharmaceutical composition or formulation comprising an effective amount of a compound of claim 1.

10           20. A method for the treatment or prevention of the symptoms or effects of HIV infection in an infected animal comprising administering said animal with a pharmaceutical composition or formulation comprising an effective amount of a compound of claim 11.

21. A method for the treatment or prevention of the symptoms or effects of HIV infection in an infected animal comprising administering said animal with a pharmaceutical combination composition or formulation comprising an effective amount of a compound of claim 1 and a second compound having anti-HIV properties.

15           22. A method for the treatment or prevention of the symptoms or effects of HIV infection in an infected animal comprising administering said animal with a pharmaceutical combination composition or formulation comprising an effective amount of a compound of claim 11 and a second compound having anti-HIV properties.

20           23. A pharmaceutical composition comprising an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient.

24. A pharmaceutical composition comprising an effective amount of a compound of claim 11, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient.

25